SCHEDULE 13G: Soleus Capital Discloses 5% Stake in UroGen Pharma Ltd.

Soleus Capital Master Fund and its affiliated entities have disclosed a 5.0% beneficial ownership stake in UroGen Pharma Ltd., holding 2,325,000 ordinary shares.

Summary

• Soleus Capital Master Fund, L.P., along with its related entities including Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and individual Guy Levy, have filed a Schedule 13G.
• The reporting group collectively beneficially owns 2,325,000 ordinary shares of UroGen Pharma Ltd.
• This ownership represents 5.0% of UroGen Pharma Ltd.'s total outstanding ordinary shares.
• The percentage is calculated based on 46,107,451 ordinary shares of UroGen Pharma Ltd. outstanding as of May 5, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on May 12, 2025.
• The shares are held directly by Soleus Capital Master Fund, L.P., with the other reporting persons having shared voting and dispositive power.
• The reporting persons disclaim beneficial ownership of these shares for any purpose other than determining their obligations under Section 13(d) of the Securities Exchange Act of 1934.
• The acquisition of these securities was not for the purpose of changing or influencing the control of UroGen Pharma Ltd.

Sentiment

Score: 6

Explanation: The filing is a standard regulatory disclosure of a significant ownership stake. While the act of an institutional investor taking a 5% stake can be viewed as a positive signal of confidence in the issuer, the document itself is purely factual and does not contain explicit positive or negative operational news.

Positives

• A significant institutional investor, Soleus Capital Master Fund, L.P., has taken a 5.0% stake in UroGen Pharma Ltd., which may be interpreted as a vote of confidence in the company's prospects.

Risks

• The reporting persons disclaim beneficial ownership of the shares held by Master Fund for any purpose other than determining their obligations under Section 13(d) of the Securities Exchange Act of 1934, as amended.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or strategic outlook.

Management Comments

• The reporting persons certify that the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing indicates a significant investment by Soleus Capital in UroGen Pharma, a biotechnology company. While the filing itself does not provide broader industry context, such an investment by a capital fund suggests a belief in the long-term potential of the pharmaceutical or biotechnology sector, or specifically UroGen Pharma's pipeline and market position.

Comparison to Industry Standards

• NA

Related Party Transactions

• The filing details the hierarchical relationship between the reporting entities (Soleus Capital Master Fund, L.P., Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy) as part of the beneficial ownership group, clarifying their roles in managing and holding the shares.

Stakeholder Impact

• Shareholders of UroGen Pharma Ltd. are informed of a new significant institutional investor, Soleus Capital Master Fund, L.P., holding a 5.0% stake, which may be perceived as a vote of confidence in the company's future.

Next Steps

• The reporting persons are obligated to file amendments to this Schedule 13G if there are material changes to their beneficial ownership or intent regarding UroGen Pharma Ltd.

Key Dates

Keywords

UroGen Pharma, Soleus Capital, Schedule 13G, Beneficial Ownership, Institutional Investor, SEC Filing, Biotechnology, Pharmaceuticals, Investment